(MENAFN- Baystreet) KULR Flat on News of Compliance
Alcoa CEO Set for Next Week's Conference
Wendy's Adds to Leadership Team
WestJet Reaches Deal With Maintenance Workers, Averting A Strike
Apple's $110 Billion Mistake Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkins - Monday, May 6, 2024
AIM Completes Ampligen Turnout
AIM ImmunoTech Inc. (NYSE: AIM) shares poked ahead to begin the first full week of May, having announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
AIM CEO Thomas K. Equels commented,“We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.”
Ampligen is currently being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19.
AIM shares captured 2.5 cents, or 6.2%, to 43 cents.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN06052024000212011056ID1108178444
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.